CMSC: Natalizumab for MS During the Covid-19 Pandemic
Overall outcomes good after Covid infection, vaccine for most patients At the recent Consortium of...
Jan 5, 2022
Overall outcomes good after Covid infection, vaccine for most patients At the recent Consortium of...
Dec 30, 2021
GI disorders most common reason for Tx discontinuation Safety is always a concern for any...
Dec 29, 2021
Prescribers cite tolerability when switching from other DMTs For those who doubt the effectiveness...
Nov 15, 2021
The COVID-19 pandemic resulted in unforeseen changes in healthcare delivery for patients with MS, and the pandemic’s swift progression led to a knowledge gap about how the virus has impacted practice patterns for MS clinicians,...
Nov 8, 2021
Currently, no research has reviewed the social consequences of the COVID-19 pandemic on patients with MS, who may experience greater social strain and more serious health consequences because of isolation measures, according to...
Nov 5, 2021
Ongoing trials may shed light on which is better In people newly diagnosed with relapsing multiple...
Oct 23, 2021
2021programbook_final_lowres Download CMSC 2021 Session Brochure (PDF)
Oct 23, 2021
2021programbook_final_lowres View CMSC 2021 Accepted Abstracts A Look at D Platform Abstracts: DMT01 Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II,...
Oct 21, 2021
This year’s Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, the leading research and educational conference for MS healthcare professionals in North America, kicks off tomorrow, October 25 through October...
Oct 21, 2021
Investigators sought to assess the impact of telerehabilitation in patients with MS during the isolation period of the COVID-19 pandemic. They conducted a retrospective analysis using medical records from adults with MS and...